讨论
chuminhua03-15 20:02
3/14,自身免疫性疾病生物技术公司Cartesian Therapeutics$Cartesian(RNAC)$ 周四在美国证券备案文件中披露,安斯泰来终止了与 Cartesian Therapeutics 的 IgG 蛋白酶候选药物 Xork 价值高达 3.5 亿美元的许可协议,距离该交易首次宣布仅一年多。
该合作于 2023 年 1 月与Selecta Biosciences...
简介:Cartesian Therapeutics, Inc.在特拉华州成立。该公司是一家临床阶段的公司,开创了治疗自身免疫性疾病的RNA细胞疗法。该公司的主要资产Descartes-08是一种潜在的first-in-class、RNA工程嵌合抗原受体T细胞疗法(rCAR-T),正处于全身性重症肌无力患者的2b期临床开发阶段,并计划在系统性红斑狼疮以及眼部自身免疫和血管性自身免疫篮子试验中开展额外的2期研究。Cartesian在马里兰州盖瑟斯堡经营一家全资拥有的最先进的cGMP生产设施。
今开:22.29 | 昨收:22.07 |
最高:23.8 | 最低:21.8 |
涨停价: | 跌停价: |
总市值:402902640 |
chuminhua03-15 20:02
3/14,自身免疫性疾病生物技术公司Cartesian Therapeutics$Cartesian(RNAC)$ 周四在美国证券备案文件中披露,安斯泰来终止了与 Cartesian Therapeutics 的 IgG 蛋白酶候选药物 Xork 价值高达 3.5 亿美元的许可协议,距离该交易首次宣布仅一年多。
该合作于 2023 年 1 月与Selecta Biosciences...
kelvinbzq02-02 21:56
Cartesian(RNAC)02-15 01:45
$Cartesian(RNAC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001133 Act: 34 Size: 83 KB 网页链接
Cartesian(RNAC)02-15 05:45
$Cartesian(RNAC)$ DEF 14A Other definitive proxy statements Accession Number: 0001140361-24-008022 Act: 34 Size: 6 MB 网页链接
Cartesian(RNAC)03-07 20:15
$Cartesian(RNAC)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001453687-24-000035 Act: 34 Size: 312 KB 网页链接
Cartesian(RNAC)03-29 05:05
$Cartesian(RNAC)$ 8-K Current report, items 5.03, 5.07, 7.01, 8.01, and 9.01 Accession Number: 0001453687-24-000048 Act: 34 Size: 261 KB 网页链接
Cartesian(RNAC)03-29 05:35
$Cartesian(RNAC)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001213900-24-027362 Act: 34 Size: 67 KB 网页链接
Cartesian(RNAC)04-02 04:35
$Cartesian(RNAC)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001453687-24-000052 Act: 34 Size: 510 KB 网页链接
Cartesian(RNAC)03-27 04:35
$Cartesian(RNAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001453687-24-000045 Size: 8 KB 网页链接
Cartesian(RNAC)04-11 04:35
$Cartesian(RNAC)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-24-091931 Act: 34 Size: 120 KB 网页链接
chuminhua03-15 20:02
3/14,自身免疫性疾病生物技术公司Cartesian Therapeutics$Cartesian(RNAC)$ 周四在美国证券备案文件中披露,安斯泰来终止了与 Cartesian Therapeutics 的 IgG 蛋白酶候选药物 Xork 价值高达 3.5 亿美元的许可协议,距离该交易首次宣布仅一年多。
该合作于 2023 年 1 月与Selecta Biosciences...查看全文
kelvinbzq02-02 21:56
伪夹头真趋势2023-11-23 17:06
回复@复利的魅力: Yongchen Lu现在Tims中国CEO 以前是汉堡王中国的CFO。都是Cartesian capital的//@复利的魅力:回复@伪夹头真趋势:汉堡王不是他经营的查看全文
$Cartesian(RNAC)$ DEF 14A Other definitive proxy statements Accession Number: 0001453687-24-000076 Act: 34 Size: 3 MB 网页链接
$Cartesian(RNAC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001453687-24-000075 Act: 34 Size: 1 MB 网页链接
$Cartesian(RNAC)$ 8-K Current report, item 8.01 Accession Number: 0001453687-24-000072 Act: 34 Size: 151 KB 网页链接
$Cartesian(RNAC)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001453687-24-000070 Size: 493 KB 网页链接
$Cartesian(RNAC)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001213900-24-032571 Act: 34 Size: 67 KB 网页链接
$Cartesian(RNAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001453687-24-000067 Size: 33 KB 网页链接
$Cartesian(RNAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001453687-24-000063 Size: 14 KB 网页链接
$Cartesian(RNAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001453687-24-000061 Size: 11 KB 网页链接
$Cartesian(RNAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001453687-24-000065 Size: 14 KB 网页链接
$Cartesian(RNAC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001453687-24-000057 Size: 20 KB 网页链接